Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Anwen Xiong(Tongji University), Lei Wang(Tongji University), Jianhua Chen(Hunan Cancer Hospital), Lin Wu(Hunan Cancer Hospital), Baogang Liu(Harbin Medical University), Jun Yao(Hebei Medical University), Hua Zhong(Shanghai Chest Hospital), Jie Li(First Affiliated Hospital of Gannan Medical University), Ying Cheng(Jilin Province Tumor Hospital), Yulan Sun(Shandong Tumor Hospital), Hui Ge(Hebei Medical University), Ji‐Fang Yao(Hebei Medical University), Qin Shi, Ming Zhou(Guangzhou Medical University), Bolin Chen(Hunan Cancer Hospital), Zhengxiang Han(Xuzhou Medical College), Jinliang Wang(Qingdao University), Qing Bu(Guangxi Medical University), Yanqiu Zhao(Henan Cancer Hospital), Junqiang Chen(Hunan Cancer Hospital), Ligong Nie(Peking University), Gaofeng Li, Xingya Li(First Affiliated Hospital of Zhengzhou University), Xinmin Yu(Zhejiang Cancer Hospital), Yinghua Ji(First Affiliated Hospital of Xinxiang Medical University), Daqiang Sun(Tianjin Chest Hospital), Xiaohong Ai(First Affiliated Hospital of University of South China), Qian Chu(Tongji Hospital), Lin Yu(Fujian Provincial Cancer Hospital), Hao Jiqing(Anhui Medical University), Dingzhi Huang(Tianjin Medical University Cancer Institute and Hospital), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Jinlu Shan(Army Medical University), Hongzhong Yang(Changsha Central Hospital), Xuewen Liu(Central South University), Jing Wang(Qingdao University), Yanhong Shang(Affiliated Hospital of Hebei University), Xiaodong Mei(Anhui Provincial Hospital), Jie Yang, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Caicun Zhou(Tongji University)
Cited by 120
Abstract
Related Papers
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al.|CA A Cancer Journal for Clinicians|2018|87.6k
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al.|New England Journal of Medicine|2016|10k
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al.|New England Journal of Medicine|2018|6.6k
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al.|New England Journal of Medicine|2018|3.7k